{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:39:18Z","timestamp":1762641558941,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.clon.2013.03.002","type":"journal-article","created":{"date-parts":[[2013,4,16]],"date-time":"2013-04-16T20:18:06Z","timestamp":1366143486000},"page":"406-430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Systemic Therapy in Men with Metastatic Castration-resistant Prostate Cancer: A\u00a0Systematic Review"],"prefix":"10.1016","volume":"25","author":[{"given":"D.A.","family":"Loblaw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Walker-Dilks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Winquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.J.","family":"Hotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clon.2013.03.002_bib1","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1200\/JCO.2006.10.1949","article-title":"American Society of Clinical Oncology. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline","volume":"25","author":"Loblaw","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.clon.2013.03.002_bib2","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2005.01.529","article-title":"Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.clon.2013.03.002_bib3","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1200\/JCO.2005.04.7423","article-title":"Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891","volume":"24","author":"Studer","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.clon.2013.03.002_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0090-4295(99)00471-9","article-title":"Clinical states in prostate cancer: toward a dynamic model of disease progression","volume":"55","author":"Scher","year":"2000","journal-title":"Urology"},{"issue":"11","key":"10.1016\/j.clon.2013.03.002_bib5","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"issue":"4","key":"10.1016\/j.clon.2013.03.002_bib6","first-page":"1220","article-title":"Management of hormone refractory prostate cancer: current standards and future prospects","volume":"160","author":"Oh","year":"1998","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clon.2013.03.002_bib7","unstructured":"Second-Line Hormonal Therapy for Men with Castration-Resistant Prostate Cancer (CRPC). American Society of Clinical Oncology Clinical Practice Guideline [cited 14 August 2012]. Available at: http:\/\/www.cancerguidelines.ca\/Guidelines\/inventory\/search.php."},{"issue":"9810","key":"10.1016\/j.clon.2013.03.002_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2013.03.002_bib9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1471-2407-6-112","article-title":"Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group","volume":"6","author":"Winquist","year":"2006","journal-title":"BMC Cancer"},{"issue":"33","key":"10.1016\/j.clon.2013.03.002_bib10","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1200\/JCO.2007.13.4536","article-title":"American Society of Clinical Oncology. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer","volume":"25","author":"Basch","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.clon.2013.03.002_bib11","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N\u00a0Engl J Med"},{"year":"2011","series-title":"Review Manager (Revman) [Computer program]. Version 5.1","key":"10.1016\/j.clon.2013.03.002_bib12"},{"issue":"9","key":"10.1016\/j.clon.2013.03.002_bib13","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/cncr.22996","article-title":"Atrasentan Phase III Study Group Institutions. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer","volume":"110","author":"Carducci","year":"2007","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.clon.2013.03.002_bib14","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.1464-410X.2010.09638.x","volume":"106","author":"James","year":"2010","journal-title":"BJU Int"},{"issue":"30","key":"10.1016\/j.clon.2013.03.002_bib15","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1200\/JCO.2011.35.6295","article-title":"Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer","volume":"29","author":"Pili","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"7 Suppl.","key":"10.1016\/j.clon.2013.03.002_bib16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/jco.2011.29.7_suppl.117","article-title":"Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC) [abstract]","volume":"29","author":"Nelson","year":"2011","journal-title":"J\u00a0Clin Oncol (Meeting Abstracts)"},{"issue":"5","key":"10.1016\/j.clon.2013.03.002_bib17","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"15 Suppl.","key":"10.1016\/j.clon.2013.03.002_bib18","article-title":"Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"30","author":"Ryan","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.clon.2013.03.002_bib19","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1200\/JCO.2005.04.8207","article-title":"Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone","volume":"24","author":"Berry","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.clon.2013.03.002_bib20","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.eururo.2007.01.104","article-title":"Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study","volume":"52","author":"Foss\u00e5","year":"2007","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clon.2013.03.002_bib21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"32","key":"10.1016\/j.clon.2013.03.002_bib22","doi-asserted-by":"crossref","first-page":"5261","DOI":"10.1200\/JCO.2008.16.9524","article-title":"Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer","volume":"26","author":"Machiels","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"15 Suppl.","key":"10.1016\/j.clon.2013.03.002_bib23","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1200\/jco.2011.29.15_suppl.4527","article-title":"Phase III, randomized, open-label study of triweekly versus biweekly docetaxel (T) as a treatment for advanced hormone-refractory prostate cancer (HRPC): final analysis of the Finnish Uro-oncological Group Study 1-2003 [abstract]","volume":"29","author":"Kellokumpu-Lehtinen","year":"2011","journal-title":"J\u00a0Clin Oncol (Meeting Abstracts)"},{"issue":"19","key":"10.1016\/j.clon.2013.03.002_bib24","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1158\/1078-0432.CCR-07-1269","article-title":"Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases","volume":"13","author":"Mathew","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.clon.2013.03.002_bib25","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdn784","article-title":"EORTC Genitourinary Tract Cancer Group. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer","volume":"20","author":"Sternberg","year":"2009","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.clon.2013.03.002_bib26","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2011.39.4767","article-title":"Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401","volume":"30","author":"Kelly","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"15 Suppl.","key":"10.1016\/j.clon.2013.03.002_bib27","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1200\/jco.2011.29.15_suppl.4528","article-title":"A\u00a0randomized, double-blind phase II trial of docetaxel plus prednisone (DP) combined with either AT-101 or placebo for the first-line therapy of metastatic castration-resistant prostate cancer (CRPC) [abstract]","volume":"29","author":"Sonpavde","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"15 Suppl.","key":"10.1016\/j.clon.2013.03.002_bib28","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1200\/jco.2012.30.15_suppl.4511","article-title":"SWOG S0421: phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC) [abstract]","volume":"30","author":"Quinn","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.03.002_bib29","unstructured":"Higano C, Saad F, Somer B, et\u00a0al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC) [abstract]. American Society of Clinical Oncology \u2013 Genitourinary Cancers Symposium 2009:LBA150. Available at: http:\/\/www.asco.org\/ASCOv2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=64&abstractID=20543."},{"key":"10.1016\/j.clon.2013.03.002_bib30","unstructured":"Small E, Demkow T, Gerritsen WR, et\u00a0al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC) [abstract]. American Society of Clinical Oncology \u2013 Genitourinary Cancers Symposium 2009:7. Available at: http:\/\/www.asco.org\/ASCOv2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=64&abstractID=20295."},{"issue":"6","key":"10.1016\/j.clon.2013.03.002_bib31","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1200\/JCO.2006.06.8197","article-title":"ASCENT Investigators. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators","volume":"25","author":"Beer","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.clon.2013.03.002_bib32","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.2010.32.8815","article-title":"Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer","volume":"29","author":"Scher","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"32","key":"10.1016\/j.clon.2013.03.002_bib33","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1200\/JCO.2008.20.1228","article-title":"Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial","volume":"27","author":"Sternberg","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"9747","key":"10.1016\/j.clon.2013.03.002_bib34","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"issue":"15 Suppl.","key":"10.1016\/j.clon.2013.03.002_bib35","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1200\/jco.2011.29.15_suppl.4515","article-title":"Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (MCRPC) [abstract]","volume":"29","author":"Ou","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"15 Suppl. 5","key":"10.1016\/j.clon.2013.03.002_bib36","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1200\/jco.2012.30.15_suppl.4519","article-title":"Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor [abstract]","volume":"30","author":"de Bono","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.clon.2013.03.002_bib37","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.eururo.2008.11.002","article-title":"Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial","volume":"55","author":"James","year":"2009","journal-title":"Eur Urol"},{"issue":"15 Suppl.","key":"10.1016\/j.clon.2013.03.002_bib38","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1200\/jco.2012.30.15_suppl.4550","article-title":"Tasquinimod and survival in men with metasatic castration-resistant prostate cancer: results of long-term follow-up of a randomized phase II placebo-controlled trial [abstract]","volume":"30","author":"Armstrong","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.03.002_bib39","doi-asserted-by":"crossref","first-page":"S483","DOI":"10.1016\/S0959-8049(11)71951-7","article-title":"Final overall survival (OS) analysis of COU-AA-301, a phase 3 study of abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) pretreated with docetaxel [abstract]","volume":"47","author":"Fizazi","year":"2011","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.clon.2013.03.002_bib40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jnci\/djr514","article-title":"Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer","volume":"104","author":"Huber","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.clon.2013.03.002_bib41","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.1999.17.10.3160","article-title":"Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial","volume":"17","author":"Hudes","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.clon.2013.03.002_bib42","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00432-011-1052-7","article-title":"Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials","volume":"137","author":"Qi","year":"2011","journal-title":"J\u00a0Cancer Res Clin Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655513001295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655513001295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:38:49Z","timestamp":1760542729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655513001295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0936655513001295"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2013.03.002","relation":{},"ISSN":["0936-6555"],"issn-type":[{"type":"print","value":"0936-6555"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Therapy in Men with Metastatic Castration-resistant Prostate Cancer: A\u00a0Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2013.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}